1
|
Zou YS, Morsberger L, Hardy M, Ghabrial J, Stinnett V, Murry JB, Long P, Kim A, Pratilas CA, Llosa NJ, Ladle BH, Lemberg KM, Levin AS, Morris CD, Haley L, Gocke CD, Gross JM. Complex/cryptic EWSR1::FLI1/ERG Gene Fusions and 1q Jumping Translocation in Pediatric Ewing Sarcomas. Genes (Basel) 2023; 14:1139. [PMID: 37372318 PMCID: PMC10298448 DOI: 10.3390/genes14061139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/17/2023] [Indexed: 06/29/2023] Open
Abstract
Ewing sarcomas (ES) are rare small round cell sarcomas often affecting children and characterized by gene fusions involving one member of the FET family of genes (usually EWSR1) and a member of the ETS family of transcription factors (usually FLI1 or ERG). The detection of EWSR1 rearrangements has important diagnostic value. Here, we conducted a retrospective review of 218 consecutive pediatric ES at diagnosis and found eight patients having data from chromosome analysis, FISH/microarray, and gene-fusion assay. Three of these eight ES had novel complex/cryptic EWSR1 rearrangements/fusions by chromosome analysis. One case had a t(9;11;22)(q22;q24;q12) three-way translocation involving EWSR1::FLI1 fusion and 1q jumping translocation. Two cases had cryptic EWSR1 rearrangements/fusions, including one case with a cryptic t(4;11;22)(q35;q24;q12) three-way translocation involving EWSR1::FLI1 fusion, and the other had a cryptic EWSR1::ERG rearrangement/fusion on an abnormal chromosome 22. All patients in this study had various aneuploidies with a gain of chromosome 8 (75%), the most common, followed by a gain of chromosomes 20 (50%) and 4 (37.5%), respectively. Recognition of complex and/or cryptic EWSR1 gene rearrangements/fusions and other chromosome abnormalities (such as jumping translocation and aneuploidies) using a combination of various genetic methods is important for accurate diagnosis, prognosis, and treatment outcomes of pediatric ES.
Collapse
Affiliation(s)
- Ying S. Zou
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Laura Morsberger
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Melanie Hardy
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Jen Ghabrial
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Victoria Stinnett
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Jaclyn B. Murry
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Patty Long
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cytogenetics Laboratory, Johns Hopkins Medicine, Baltimore, MD 21205, USA
| | - Andrew Kim
- Biotechnology, Johns Hopkins University, Baltimore, MD 21205, USA;
| | - Christine A. Pratilas
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, USA; (C.A.P.); (N.J.L.); (B.H.L.); (K.M.L.)
| | - Nicolas J. Llosa
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, USA; (C.A.P.); (N.J.L.); (B.H.L.); (K.M.L.)
| | - Brian H. Ladle
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, USA; (C.A.P.); (N.J.L.); (B.H.L.); (K.M.L.)
| | - Kathryn M. Lemberg
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, USA; (C.A.P.); (N.J.L.); (B.H.L.); (K.M.L.)
| | - Adam S. Levin
- Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA;
| | - Carol D. Morris
- Orthopaedic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
| | - Lisa Haley
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Christopher D. Gocke
- Johns Hopkins Genomics, Baltimore, MD 21205, USA (J.B.M.)
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - John M. Gross
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| |
Collapse
|
2
|
Ali K, Habib MB, Taha NM, Abdalhadi AM, Hammamy R. Pleural Effusion Revealing a Diagnosis of Ewing Sarcoma. Cureus 2021; 13:e20439. [PMID: 35047276 PMCID: PMC8760035 DOI: 10.7759/cureus.20439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/14/2021] [Indexed: 11/14/2022] Open
Abstract
Pleural effusion can rarely present as an initial manifestation of Ewing sarcoma. We illustrate a case of a young male adult who was admitted with pleural effusion that led to the diagnosis of Ewing sarcoma.
Collapse
|
3
|
Ramkumar DB, Ramkumar N, Miller BJ, Henderson ER. Risk factors for detectable metastatic disease at presentation in Ewing sarcoma - An analysis of the SEER registry. Cancer Epidemiol 2018; 57:134-139. [PMID: 30412903 DOI: 10.1016/j.canep.2018.10.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 10/06/2018] [Accepted: 10/24/2018] [Indexed: 02/04/2023]
Abstract
BACKGROUND Ewing family of tumors (EFT) represents the second-most common primary bone malignancy in children and adolescents. Approximately 25% of patients have radiographically detectable metastatic disease at presentation and experience poorer five-year survival, yet risk factors for metastatic disease at presentation are poorly characterized. We sought to study patient characteristics associated with metastatic disease upon presentation for patients with EFT. METHODS We identified EFT cases in the Surveillance, Epidemiology, and End Results Program (SEER) registry from 2004 to 2012. Using univariate analyses and multivariable logistic regression, we explored the relationship between demographic and clinical factors and the presence of detectable metastatic disease at presentation. RESULTS Among 870 EFT cases, 35% (n = 304) presented with detectable metastatic disease. These patients were commonly older (>24 years: 28% vs 19%, p = 0.002) and had a primary tumor site in the axial skeleton (56% vs 44%, p < 0.001). After adjusting for all covariates, compared to patients <11 years, those >24 years old faced a two-fold increase in the odds of metastatic disease (OR = 1.99, 95% CI: 1.17-3.38). Axial (OR = 2.31, 95% CI: 1.58-3.37) and "other" (OR = 2.35, 95% CI: 1.15-4.81) tumor locations had more than twice the likelihood of presenting with metastatic disease, compared to extremity tumor sites. Increasing tumor size conferred up to a three-fold increase in odds of metastatic disease (pTrend <0.001). CONCLUSIONS Advanced age, axial tumor location, and increasing tumor size are associated with increased odds of detectable metastatic disease upon presentation with EFT. Although these characteristics are not modifiable, they provide objective factors that may inform patient counseling of metastatic risk.
Collapse
Affiliation(s)
- Dipak B Ramkumar
- Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, United States.
| | - Niveditta Ramkumar
- The Dartmouth Institute of Health Policy and Clinical Practice, Williamson Translational Research Building Level 5, One Medical Center Drive, Lebanon, NH 03756, United States.
| | - Benjamin J Miller
- Department of Orthopedics and Rehabilitation, 200 Hawkins Drive, Iowa City, IA, 52242, United States.
| | - Eric R Henderson
- Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, United States.
| |
Collapse
|
4
|
VAN Noord RA, Thomas T, Krook M, Chukkapalli S, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA. Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. ACTA ACUST UNITED AC 2017; 31:779-791. [PMID: 28882943 DOI: 10.21873/invivo.11131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 07/14/2017] [Accepted: 07/17/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Advances in cancer therapeutics depend on reliable in vivo model systems. To develop biologically relevant xenografts, ultrasound was utilized for tissue-directed implantation of neuroblastoma (NB) cell line and patient-derived tumors in the adrenal gland, and for renal subcapsular engraftment of Ewing's sarcoma (ES). MATERIALS AND METHODS NB xenografts were established by direct adrenal injection of luciferase-transfected NB cell lines (IMR32, SH-SY5Y, SK-N-BE2) or NB patient-derived tumor cells (UMNBL001, UMNBL002). ES xenografts were established by renal subcapsular injection of TC32, A673, CHLA-25, or A4573 cells. Progression was monitored by in vivo imaging. RESULTS Tumors progressed to local disease with metastasis evident by 5 weeks. Metastatic sites included cortical bone, lung, liver, and lymph nodes. Xenografted tumors retained immunochemical features of the original cancer. CONCLUSION Human NB adrenal xenografts, including two patient-derived orthotopic, and ES renal subcapsular xenografts were established by ultrasound without open surgery. Tissue-directed implantation is an effective technique for developing metastatic preclinical models.
Collapse
Affiliation(s)
- Raelene A VAN Noord
- Department of Surgery, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Tina Thomas
- Department of Surgery, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Melanie Krook
- Department of Pathology, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Sahiti Chukkapalli
- Department of Surgery, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Mark J Hoenerhoff
- Unit for Laboratory Animal Medicine, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Jonathan R Dillman
- Department of Radiology, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Elizabeth R Lawlor
- Department of Pathology, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A.,Department of Pediatrics, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Valerie P Opipari
- Department of Pediatrics, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A
| | - Erika A Newman
- Department of Surgery, C.S Mott Children's and Women's Hospital, Mott Solid Tumor Oncology Program, The University of Michigan Medical School, Ann Arbor, MI, U.S.A.
| |
Collapse
|
5
|
|
6
|
Berghuis D, Santos SJ, Baelde HJ, Taminiau AHM, Maarten Egeler R, Schilham MW, Hogendoorn PCW, Lankester AC. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+
T-lymphocyte infiltration and affect tumour progression. J Pathol 2010; 223:347-57. [DOI: 10.1002/path.2819] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2010] [Revised: 10/29/2010] [Accepted: 10/29/2010] [Indexed: 01/19/2023]
|
7
|
Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1). J Pediatr Hematol Oncol 2010; 32:e331-7. [PMID: 20962673 DOI: 10.1097/mph.0b013e3181ee4d16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Ewing sarcoma (ES) is one of the most malignant tumors in children and young adults. We present here a new ES cell line, SS-ES-1, established from the left thoracic tumor of a 16-year-old female patient. The SS-ES-1 cells retained genotype, morphology, and growth rate for over 150 passages. Immunocytochemical staining showed the strong immunoreactivity for cytokeratin, epithelial membrane antigen, neurofilament, CD99, P53, Ki-67, platelet-derived growth factor receptor-β, estrogen receptor-α (ER-α), and Bcl-2, but no reactivity for glial fibrillary acidic protein, epidermal growth factor receptor, and HER-2/neu. The presence of the type 1 EWS/FLI-1 fusion transcripts was confirmed by reverse transcriptase-polymerase chain reaction. On the basis of the MTT assay results, GW2974, a dual inhibitor of epidermal growth factor receptor and HER-2/neu, exhibited only a weak cytotoxic response in SS-ES-1 cells. In contrast, tyrphostin A9, a specific inhibitor of platelet-derived growth factor receptor, had a high cytotoxic effect against these cells. Surprisingly, it was found that SS-ES-1 cells displayed a high sensitivity to 4OH-tamoxifen. In conclusion, the SS-ES-1 cell line shows unique cellular properties, which makes it a useful model for studying various aspects of the biology of ES. In addition, the results suggest that ER can be a good therapeutic target for ER + ES.
Collapse
|
8
|
Berghuis D, de Hooge ASK, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AHM, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJM, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PCW, Lankester AC. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009; 218:222-31. [PMID: 19274709 DOI: 10.1002/path.2537] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Ewing sarcoma (EWS) is a tumour most commonly arising in bone, although on occasion in soft tissue, with a poor prognosis in patients with refractory or relapsed disease, despite multimodal therapy. Immunotherapeutic strategies based on tumour-reactive T and/or natural killer cells may improve the treatment of advanced-stage EWS. Since cellular immune recognition critically depends on human leukocyte antigen (HLA) expression, knowledge about HLA expression in EWS is crucial in the design of cellular immunotherapeutic strategies. Constitutive and IFNgamma-induced HLA class I expression was analysed in EWS cell lines (n = 6) by flow cytometry, using antibodies against both monomorphic and allele-specific antigens. Expression of antigen processing pathway components and beta-2 microglobulin (beta2m) was assessed by western blot. Expression of class II transactivator (CIITA), and its contribution to HLA class II expression, was evaluated by qRT-PCR, transduction assays, and flow cytometry. beta2m/HLA class I and class II expression was validated in EWS tumours (n = 67) by immunofluorescence. Complete or partial absence of HLA class I expression was observed in 79% of EWS tumours. Lung metastases consistently lacked HLA class I and sequential tumours demonstrated a tendency towards decreased expression upon disease progression. Together with absent or low constitutive expression levels of specific HLA class I loci and alleles, and differential induction of identical alleles by IFNgamma in different cell lines, these results may reflect the existence of an immune escape mechanism. Inducible expression of TAP-1/-2, tapasin, LMP-2/-7, and the beta2m/HLA class I complex by IFNgamma suggests that regulatory mechanisms are mainly responsible for heterogeneity in constitutive class I expression. EWSs lack IFNgamma-inducible HLA class II, due to lack of functional CIITA. The majority of EWS tumours, particularly if advanced-stage, exhibit complete or partial absence of both classes of HLA. This knowledge will be instrumental in the design of cellular immunotherapeutic strategies for advanced-stage EWS.
Collapse
Affiliation(s)
- Dagmar Berghuis
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Palmerini E, Staals EL, Ferrari S, Bacci G. Diagnosis and prognosis for the Ewing family of tumors. ACTA ACUST UNITED AC 2009; 3:445-52. [PMID: 23485211 DOI: 10.1517/17530050902832830] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Ewing's sarcoma was first described by James Ewing in 1921. It is the second most common bone sarcoma seen in children, adolescents and young adults after osteosarcoma and belongs to the group of 'small round blue cell tumors', showing an aggressive natural history. Once almost invariably fatal and treated only with palliative radiation, thanks to a multidisciplinary approach, the probability of survival at 5 years is now ∼ 65 - 75% for patients with localized disease. This percentage is no more than 20 - 25% for patients with metastatic disease at presentation. OBJECTIVE To review epidemiology, diagnosis and prognosis of Ewing's sarcoma family tumors (EFT) of bone. This entity includes a wide spectrum of tumors, from the less differentiated or classic Ewing's sarcoma to the more differentiated peripheral neuroectodermal tumor. A translocation involving the EWS gene on the chromosome 22 band q12 is characteristic of EFTs. CONCLUSION A complete clinical and radiological assessment is essential for initial patient evaluation. Owing to the rarity of this entity, whenever an EFT is suspected patients should be referred to a bone tumor treatment center before a diagnostic biopsy is performed. The molecular characterization of chromosomal translocations has an important role in the diagnosis of EFT.
Collapse
Affiliation(s)
- Emanuela Palmerini
- Istituto Ortopedico Rizzoli, Department of Musculoskeletal Oncology, Via Pupilli 1, 40136 Bologna, Italy +39 051 6366 829 ; +39 051 6366 277 ;
| | | | | | | |
Collapse
|
10
|
Ushigome S, Shimoda T, Nikaido T, Nakamori K, Miyazawa Y, Shishikura A, Takakuwa T, Ubayama Y, Spjut HJ. Primitive Neuroectodermal Tumors of Bone and Soft Tissue. Pathol Int 2008. [DOI: 10.1111/j.1440-1827.1992.tb03093.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Masoom S, Venkataraman G, Hammadeh R, Wojcik EM. Ewing's sarcoma/primitive neuroectodermal tumour in a possible primary testicular location. Pathology 2007; 39:599-601. [PMID: 18027267 DOI: 10.1080/00313020701684359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Hatori M, Doi H, Watanabe M, Sasano H, Hosaka M, Kotajima S, Urano F, Hata J, Kokubun S. Establishment and characterization of a clonal human extraskeletal Ewing's sarcoma cell line, EES1. TOHOKU J EXP MED 2007; 210:221-30. [PMID: 17077599 DOI: 10.1620/tjem.210.221] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Ewing's sarcoma, a small round cell sarcoma arising in soft tissue as well as the bone, is one of the most malignant tumors in children and young adults. Few established cell lines of extraskeletal Ewing's sarcoma (EES) have been reported, which made it difficult to examine the biological features of EES. Therefore, we have established a new clonal cell line of EES. We report its morphological characters, results of chromosomal and immunohistochemical analysis. A piece of tumor obtained from the 18-year-old female patient with EES was xenografted in a nude mouse. In vitro subcultured cells were then obtained from this xenograft. A clonal cell line was subsequently established by limiting dilution and designated EES1. EES1 cells had a doubling time of 24 hours. In the xenografted tumor, the cells expressed vimentin, CD99 (MIC2), neuron specific enolase (NSE) and cytokeratin. The original tumor cells also expressed vimentin, CD 99, and NSE, but was negative for cytokeratin. The morphological and immunohistochemical features of this cell line established, except for cytokeratin expression, were consistent with those of the primary tumor. Cytogenetic analysis of EES1 revealed chromosomal translocation of t(11; 12)(q24;ql2). The chimeric fusion of the Ewing's sarcoma gene in band 22q12 with the Friend leukemia virus integration-1 gene in band 11q24 was also demonstrated. Fluorescence in situ hybridization further confirmed the presence of translocation involving the Ewing's sarcoma gene in both the primary tumor and EES1 cells. In conclusion, we have established a human EES cell line EES1, which will provide a useful model for studying various aspects of human EES.
Collapse
Affiliation(s)
- Masahito Hatori
- Department of Orthopaedic Surgery, Tohoku University School of Medicine, Sendai, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Yamada K, Sugiura H, Takahashi M. Single center experience of treatment of Ewing's family of tumors in Japan. J Orthop Sci 2006; 11:34-41. [PMID: 16437346 DOI: 10.1007/s00776-005-0974-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2005] [Accepted: 10/28/2005] [Indexed: 11/29/2022]
Abstract
BACKGROUND Japanese patients with the Ewing's family of tumors (EFTs) reportedly have a worse prognosis than their European Caucasian counterparts. However, details of the prognosis of Japanese EFT patients have not been clearly defined because of the lack of representative clinical studies of the results of contemporary, multidisciplinary treatments. METHODS The present study analyzed the outcome of 19 consecutive patients with EFTs who were treated with a multidisciplinary approach at a single institution. Combination chemotherapy consisting of vincristine, actinomycin D, Adriamycin (doxorubicin), and ifosfamide was administered as induction chemotherapy. Local therapy was administered individually, considering various factors, with the ultimate aim of complete surgical resection. Nine patients who satisfied the inclusion criteria received high-dose chemotherapy with peripheral blood stem cell rescue as a consolidation treatment. RESULTS The 3-year overall and event-free survival rates were 62% and 51%, respectively, which were comparable to results from Western countries, although the number of subjects was too small to allow definitive conclusions to be drawn. CONCLUSIONS There is a clear need to investigate the results of treatment of Japanese EFT patients in a multiinstitutional, prospective clinical study.
Collapse
Affiliation(s)
- Kenji Yamada
- Department of Orthopaedics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan
| | | | | |
Collapse
|
14
|
López-Guerrero JA, Navarro S, Noguera R, Carda C, Fariñas SC, Pellín A, Llombart-Bosch A. Mutational Analysis of the c-KIT AND PDGFR?? in a Series of Molecularly Well-Characterized Synovial Sarcomas. ACTA ACUST UNITED AC 2005; 14:134-9. [PMID: 16106193 DOI: 10.1097/01.pas.0000176766.33671.b6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The c-KIT and the platelet-derived growth factor receptor alpha (PDGFRalpha) have been shown to be important for tumor growth and progression in several soft-tissue sarcomas, including synovial sarcomas (SSs). It has been suggested that these c-KIT-positive cases might benefit from a tyrosine kinase inhibitor therapy. In this study, we analyze a series of SSs to investigate the presence of c-KIT and PDGFRalpha mutations with the aim of selecting those for a more adequate and appropriate therapy. We analyzed fresh-frozen tissues from 12 SSs (8 primary tumors and 4 nude mice xenotransplants from primary tumors). RNA was extracted to identify the presence of the SYT-SSX gene fusion to confirm the SS diagnosis. Mutational analysis of exons 9, 11, 13, and 17 of c-KIT and exons 12 and 18 of PDGFRalpha was performed by direct sequencing. Immunohistochemical analysis of c-KIT, PDGFRalpha, and p-PDGFRalpha was also performed. All analyzed cases showed the presence of SYT-SSX gene fusion transcripts confirming the diagnosis of SS, 10 carried the SYT-SSX1 fusion, and 2 the SYT-SSX2. Immunohistochemical analysis showed expression of c-KIT in 3 cases in which no molecular alterations were detected. For the PDGFRalpha, we observed an in-frame deletion of codons 554 and 555 in a case which also showed a strong immunopositivity for the phosphorylated form of PDGFRalpha. PDGFRalpha expression was observed in 8 cases. We suggest that a more exhaustive mutational analysis of the c-KIT and PDGFRalpha genes should be performed to ascertain which cases would really benefit from a tyrosine kinase inhibitor therapy in SS.
Collapse
|
15
|
López-Guerrero JA, López-Ginés C, Pellín A, Carda C, Llombart-Bosch A. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. ACTA ACUST UNITED AC 2004; 13:81-91. [PMID: 15167009 DOI: 10.1097/00019606-200406000-00004] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Osteosarcoma (OS) displays complex karyotypes with numerical changes as well as structural abnormalities suggesting that several oncogenes and tumor suppressor genes may be implicated in the biology of OS. The aim of our study was to investigate the possible implication of the molecular alterations of the G1 to S-phase checkpoint genes in the pathogenesis of OS. We analyzed samples from 29 patients and found molecular alterations of the RB and TP53 genes in 6 (21%) and 3 (10%) cases, respectively. Homozygous deletion of the INK4A/ARF locus and methylation of INK4A was detected in 3 (10%) and 2 (7%) cases, respectively. CDK4 and MDM2 co-amplification was observed in 1 case (3%). Cyclin D3 is differentially expressed in a greater proportion than D1- and D2-type cyclins. Cytogenetically, all cases had complex karyotypes being especially significant the losses of the chromosomes 4, 13, and 17. As a whole, 11 of 29 (38%) analyzed OS presented alterations in some of the analyzed G1 to S-phase checkpoint genes. These alterations were more frequently present in adults (P = 0.032). All patients with genetic alterations in the G1/S-phase checkpoint died during their clinical follow-up, whereas more than 53% of the remaining cases were alive in this period (P = 0.007). Hence, in the pathogenesis of human OS, deregulation of the G1/S checkpoint genes, especially RB, TP53, and INK4/ARF locus, plays an important role and defines a subgroup of patients with a poor outcome.
Collapse
|
16
|
|
17
|
|
18
|
Antunes NL, Lellouch-Tubiana A, Kalifa C, Delattre O, Pierre-Kahn A, Rosenblum MK. Intracranial Ewing sarcoma/'peripheral' primitive neuroectodermal tumor of dural origin with molecular genetic confirmation. J Neurooncol 2001; 51:51-6. [PMID: 11349881 DOI: 10.1023/a:1006432919281] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Ewing sarcoma/'peripheral' primitive neuroectodermal tumor (ES/pPNET) is the designation given to a family of small cell neoplasms that typically arise in bone or soft tissue and are unified by their common expression of the MIC2 antigen and specific translocations involving a gene on chromosome 22q12 [the most common being t(11;22)(q24;q12)]. ES/pPNET of intracranial origin is extraordinary. We report the case of a 6-year-old boy with a large left frontal region mass that adhered to dura and was extracerebral at surgery. Histologic study revealed a high-grade, undifferentiated-appearing neoplasm of small cell type that was negative on immunostudy for glial fibrillary acidic protein, synaptophysin, desmin, leukocyte common antigen, smooth muscle actin and epithelial membrane antigen, but positive for vimentin and neuron-specific enolase and diffusely labeled by antibody O13 (which recognizes the MIC2 gene product). RNA-based polymerase chain reaction assay confirmed the diagnosis of ES/pPNET by demonstrating fusion transcripts indicative of t(11;22) translocation. Bone scan, computerized tomography of the chest and bone marrow examination revealed no systemic tumor. The limited observations published to date suggest that primary intracranial ES/pPNET is most likely to present in childhood as a circumscribed, contrast-enhancing and dural-based extracerebral mass. It must be distinguished from a variety of small cell neoplasms, particularly PNETs of central neuroepithelial origin.
Collapse
Affiliation(s)
- N L Antunes
- Department of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
19
|
López-Guerrero JA, Pellín A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. J Transl Med 2001; 81:803-14. [PMID: 11406642 DOI: 10.1038/labinvest.3780290] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
SUMMARY The EWS-ETS rearrangements, and their respective fusion gene products, are specifically associated with histopathologically Ewing family tumors (EFT). These translocations are implicated in generating malignant transformation of EFT, but the presence of additional genetic alterations must be considered in the pathogenesis of such tumors. We analyzed 26 samples (biopsies and/or nude mice xenotransplants) collected from 19 patients with an EFT to determine whether molecular and cytogenetic alterations of the G(1)/S checkpoint genes are implicated in the pathogenesis of EFT. We found inactivating p53 mutations in three (16%) cases, which correlated with a loss of p21(WAF1/Cip1) expression and with a monosomy of chromosome 17 in two cases. Homozygous deletion of the p16(INK4A)/p14(ARF) gene was detected in four (21%) cases, three with codeletion of the p15(INK4B) gene and with chromosome 9 abnormalities. In all of these cases, expression of the implicated genes was absent. Hypermethylation of the p16(INK4A) and p15(INK4B) genes was detected in two (10%) and three (16%) cases, respectively, and was correlated with a low level of gene expression. Neither cyclin D1, nor MDM2 and CDK4 amplification was observed. Kaplan-Meier analysis showed that patients with tumors carrying homozygous deletion of the 9p21 locus, or point mutations of the p53 gene, had poorer outcomes than those without these molecular alterations (p = 0.005). In conclusion, 58% (11 of 19) of the analyzed patients showed genetic or epigenetic alterations in either the 9p21 locus or p53 tumor suppressor genes, defining a subgroup of patients with poor clinical outcome. This fact points to an important role of the G(1)/S cell cycle checkpoint dysregulation in the pathogenesis of EFT.
Collapse
Affiliation(s)
- J A López-Guerrero
- Department of Pathology, School of Medicine, University of Valencia, Valencia, Spain.
| | | | | | | | | |
Collapse
|
20
|
Udayakumar AM, Sundareshan TS, Goud TM, Devi MG, Biswas S, Appaji L, Arunakumari BS, Rajan KR, Prabhakaran PS. Cytogenetic characterization of Ewing tumors using fine needle aspiration samples. a 10-year experience and review of the literature. CANCER GENETICS AND CYTOGENETICS 2001; 127:42-8. [PMID: 11408064 DOI: 10.1016/s0165-4608(00)00417-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Chromosomal analysis was performed in fine needle aspiration samples of 98 primary Ewing tumors (ETs) prior to treatment. Among the 58 (59.18%) successful cultures, t(11;22)(q24;q12) was observed in 87.9% and 6.8% had abnormalities other than t(11;22), viz., del(22)(q12), der(16)t(1;16)(q12;q11), and variant t(8;22)(q24;q12). Involvement of breakpoints 1q21, 1q22, 3p14, 16q22, and 17p13 was also observed. Numerical abnormalities such as trisomies 8 and 12 were found in 29.3% and 20.6% and trisomy 18 in 17.2%. An attempt was made to evaluate the role of these additional changes in the process of tumor development, metastasis, and progression of the disease. This is the largest cytogenetic study on ET from a single center using a simple and reliable technique of fine-needle aspiration culture. The literature on cytogenetics of ET is reviewed.
Collapse
MESH Headings
- Adolescent
- Adult
- Biopsy, Needle
- Bone Neoplasms/genetics
- Bone Neoplasms/pathology
- Child
- Child, Preschool
- Chromosome Aberrations/genetics
- Chromosome Disorders
- Chromosomes, Human, 1-3/genetics
- Chromosomes, Human, 16-18/genetics
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 22/genetics
- Cytogenetics
- Female
- Humans
- Male
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/pathology
Collapse
Affiliation(s)
- A M Udayakumar
- Cytogenetics Unit, Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka 560-029, India.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Noguera R, Pellín A, Navarro S, Carda C, Llombart-Bosch A. Translocation (10;11;22)(p14;q24;q12) characterized by fluorescence in situ hybridization in a case of Ewing's tumor. DIAGNOSTIC MOLECULAR PATHOLOGY : THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY, PART B 2001; 10:2-8. [PMID: 11277391 DOI: 10.1097/00019606-200103000-00002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
It is well recognized that the identification by classic cytogenetics of t(11;22)(q24;q12) is a useful aid in the accurate diagnosis of Ewing's sarcoma and related tumors. This translocation induces the EWS/FLI-1 fusion transcript, which can be detected by reverse transcription-polymerase chain reaction. Recent studies have also used fluorescence in situ hybridization (FISH) to demonstrate the translocation. The authors coupled classic cytogenetics and FISH on tumor cells from the original specimen, the local recurrence, and the pulmonary metastasis as well as from the xenografted tumors in a case of extraosseous Ewing's sarcoma. FISH analysis not only confirmed the cytogenetic results but also allowed the identification of a tumor-specific chromosome change, consistent with a complex translocation, t(10;11;22), as well as revealed other chromosomal rearrangements on both metaphases and interphase nuclei of each material. In addition this technique served to identify, in the interphase nuclei of the original tumor, the clone that became dominant, from the cytogenetic point of view, in the lung metastasis and in the nude mice xenografted tumors. Current results indicate that the use of FISH on metaphases and interphase nuclei is an easy and reliable approach to complement or even to substitute classic cytogenetic studies for the detection of specific chromosomal rearrangements, especially for determining complex translocations and for describing tumoral clones with different cytogenetic markers.
Collapse
MESH Headings
- Bone Neoplasms/genetics
- Bone Neoplasms/pathology
- Bone Neoplasms/therapy
- Child
- Chromosomes, Human, Pair 10/genetics
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 22/genetics
- Combined Modality Therapy
- DNA, Neoplasm/analysis
- Fatal Outcome
- Female
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization, Fluorescence
- Karyotyping
- Leg/pathology
- Lung Neoplasms/secondary
- Oncogene Proteins, Fusion/analysis
- Proto-Oncogene Protein c-fli-1
- RNA-Binding Protein EWS
- Reverse Transcriptase Polymerase Chain Reaction
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/secondary
- Sarcoma, Ewing/therapy
- Sequence Analysis, DNA
- Transcription Factors/analysis
- Translocation, Genetic
Collapse
Affiliation(s)
- R Noguera
- Department of Pathology, Medical School, University of Valencia, Spain.
| | | | | | | | | |
Collapse
|
22
|
Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C, Couvreur P. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000; 279:401-6. [PMID: 11118299 DOI: 10.1006/bbrc.2000.3963] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
EWS Fli-1, a fusion gene resulting from a t(11;22) translocation is found in 90% of both Ewing's sarcoma and primitive neuroectodermal tumor (PNET). In the present study, we show that recently developed polyisobutylcyanoacrylate nanocapsules with an aqueous core were able to encapsulate efficiently high amounts of phosphorothioate oligonucleotides (ODN) directed against EWS Fli-1 chimeric RNA. Release of these ODN in serum medium was shown to be biphasic which was explained by the presence of two types of nanocapsules able to release ODN with different kinetics. In addition, nanocapsules were found to provide protection of these oligonucleotides from the degradation in serum. These ODN nanocapsules permitted to obtain inhibition of Ewing sarcoma-related tumor in mice after intratumoral injection of a cumulative dose as low as 14.4 nanomoles. This new type of non viral vector shows great potential for in vivo administration of oligonucleotides.
Collapse
Affiliation(s)
- G Lambert
- Laboratoire de physico-chimie, UMR CNRS 8612, Châtenay-Malabry, France
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Llombart-Bosch A, Pellín A, Carda C, Noguera R, Navarro S, Peydró-Olaya A. Soft tissue Ewing sarcoma--peripheral primitive neuroectodermal tumor with atypical clear cell pattern shows a new type of EWS-FEV fusion transcript. DIAGNOSTIC MOLECULAR PATHOLOGY : THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY, PART B 2000; 9:137-44. [PMID: 10976720 DOI: 10.1097/00019606-200009000-00003] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This study describes a new case of Ewing sarcoma (ES)-peripheral primitive neuroectodermal tumor (pPNET) with unusual phenotype and fusion gene structure. The tumor located in the inguinal area of a 15-year-old boy showed a highly aggressive behavior with hematogenous metastases after intensive chemotherapy and bone marrow transplant, causing death 28 months after diagnosis. The tumor displayed a clear cell pattern, and several neuroectodermal markers proved positive both in the original tumor and in xenografts. This neuroectodermal character was confirmed by electron microscopy. Moreover, cytogenetically the tumor has an unusual chromosomal rearrangement, t(2;22)(q13;q22,t(3;18)(p21;q23); representing a new EWS-FEV fusion type in which exon 7 of EWS gene is fused with exon 2 of FEV gene. This is the third published study of an ES-pPNET showing EWS-FEV fusion described, but it is the first study of a tumor with the aforementioned fusion points. These findings support the genetic and morphologic heterogeneity existing within the group of ES-pPNET tumors.
Collapse
MESH Headings
- Adolescent
- Animals
- Chromosomes, Human, Pair 2/genetics
- Chromosomes, Human, Pair 2/ultrastructure
- Chromosomes, Human, Pair 22/genetics
- Chromosomes, Human, Pair 22/ultrastructure
- Combined Modality Therapy
- Disease Progression
- Exons/genetics
- Fatal Outcome
- Groin
- Humans
- Karyotyping
- Male
- Mice
- Mice, Nude
- Neoplasm Metastasis
- Neoplasm Proteins/analysis
- Neuroectodermal Tumors, Primitive/genetics
- Neuroectodermal Tumors, Primitive/pathology
- Oncogene Proteins, Fusion/genetics
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/pathology
- Soft Tissue Neoplasms/genetics
- Soft Tissue Neoplasms/pathology
- Translocation, Genetic/genetics
- Transplantation, Heterologous
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A Llombart-Bosch
- Department of Pathology, Medical School of University of Valencia, Spain
| | | | | | | | | | | |
Collapse
|
24
|
Gu M, Antonescu CR, Guiter G, Huvos AG, Ladanyi M, Zakowski MF. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol 2000; 24:410-6. [PMID: 10716155 DOI: 10.1097/00000478-200003000-00010] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) are characterized by the presence of the specific t(11;22)(q24;q12) or variants thereof, producing diagnostic EWS fusion transcripts. Cytokeratin has been reported sporadically to be expressed in some cases of ES/PNET. However, its prevalence has not been assessed systematically in a series of cases with confirmatory molecular or cytogenetic evidence of a diagnostic translocation. We present in detail three index patients in whom strong cytokeratin immunoreactivity was a confounding factor in the diagnosis. To establish further the prevalence of cytokeratin immunoreactivity in a series of well-characterized ES/PNET, we then performed immunohistochemical studies with antibodies CAM5.2 and AE1/AE3 on 50 cases of ES/PNET diagnosed at Memorial Sloan-Kettering Cancer Center in which molecular evidence of a specific ES/PNET-associated translocation were available. Immunoreactivity to cytokeratin was present in 10 cases (20%), in five diffusely and five focally. There was no significant association between cytokeratin expression and the following parameters: patient age, sex, skeletal and extraskeletal primary site, and the type of EWS fusion transcript. Cytokeratin expression, a manifestation of epithelial differentiation, is present in as many as 20% of ES/PNET in either a diffuse or focal pattern.
Collapse
Affiliation(s)
- M Gu
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
25
|
Noguera R, Navarro S, Carda C, Peydró-Olaya A, Llombart-Bosch A. Near-haploidy in a malignant sacrococcygeal teratoma. CANCER GENETICS AND CYTOGENETICS 1999; 108:70-4. [PMID: 9973927 DOI: 10.1016/s0165-4608(98)00115-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Cytogenetic analysis of a malignant sacrococcygeal teratoma in an adult patient revealed near-haploid (77%), near-diploid (19%), and polyploid (4%) cells. The near-haploid cells had a karyotype of 25,XX,der(5)t(5;7)(p15;p13),+7,der(9)t(6;9)(p21;q34),r(17)(p13q25) . In the near-diploid and polyploid cells identical copies of the structural chromosomal changes were found. Although some of the anomalies observed appear unique to this case, a common breakpoint in chromosome 6 was previously reported as specific in a subgroup of extragonadal germ cell tumors of adults.
Collapse
MESH Headings
- Aged
- Chromosome Mapping
- Chromosomes, Human, Pair 5
- Chromosomes, Human, Pair 6
- Chromosomes, Human, Pair 7
- Chromosomes, Human, Pair 9
- Coccyx
- Diploidy
- Fatal Outcome
- Female
- Haploidy
- Humans
- Karyotyping
- Ploidies
- Polyploidy
- Sacrum
- Spinal Neoplasms/diagnostic imaging
- Spinal Neoplasms/genetics
- Spinal Neoplasms/pathology
- Spinal Neoplasms/therapy
- Teratoma/diagnostic imaging
- Teratoma/genetics
- Teratoma/pathology
- Teratoma/therapy
- Tomography, X-Ray Computed
- Translocation, Genetic
Collapse
Affiliation(s)
- R Noguera
- Department of Pathology, Medical School, University of Valencia, Spain
| | | | | | | | | |
Collapse
|
26
|
Halliday BE, Slagel DD, Elsheikh TE, Silverman JF. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopathol 1998; 19:410-6. [PMID: 9839129 DOI: 10.1002/(sici)1097-0339(199812)19:6<410::aid-dc2>3.0.co;2-z] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Ewing's sarcoma (ES) and peripheral neuroectodermal tumor (PNET) are considered in the differential diagnosis of small round blue cell tumors of infancy and childhood which includes neuroblastoma, rhabdomyosarcoma and malignant lymphoma. Fine-needle aspiration diagnosis of these neoplasms can be particularly difficult when the neoplasms are composed of poorly differentiated cells or fail to produce a stroma. MIC-2 is a highly sensitive and specific marker for the PNET/ES group of neoplasms and has been studied extensively in surgical pathology. Other small blue cell neoplasms including rhabdomyosarcoma, blastemal Wilm's tumor, and lymphoblastic lymphoma have also shown positivity, but the staining reactions are usually weak and focal. The utility of this marker in the differential of small blue cell neoplasms in cytologic material has not been examined. Twenty cases of small blue cell neoplasms obtained by fine-needle aspiration (FNA) were studied. MIC-2 antibody was applied retrospectively to formalin-fixed cell block material and destained alcohol-fixed and air-dried cytologic preparations. These cases include primitive neuroectodermal tumor (five cases), Ewing's sarcoma (two cases), neuroblastoma (four cases), Wilms's tumor (four cases), lymphoblastic lymphoma (two cases), and small-cell carcinoma (three cases). The cases were judged positive when the majority of the cells showed cytoplasmic staining. Diffuse cytoplasmic staining was observed in all seven cases of PNET/ES. Staining could be seen on the destained air-dried smears (three cases), fixed smears (two cases), or the cell block material (two cases). None of the other 13 small blue cell neoplasms showed positive staining. We conclude that MIC-2 is a sensitive and specific marker for the PNET/ES group of neoplasms in specimens from formalin-fixed cell block, air-dried, and alcohol-fixed cytologic material and is useful in the differential diagnosis of small blue cell tumors.
Collapse
MESH Headings
- 12E7 Antigen
- Adolescent
- Adult
- Aged
- Animals
- Antigens, CD/analysis
- Carcinoma, Neuroendocrine/diagnosis
- Carcinoma, Neuroendocrine/pathology
- Cell Adhesion Molecules/analysis
- Child
- Child, Preschool
- Diagnosis, Differential
- Female
- Humans
- Immunoenzyme Techniques
- Infant
- Male
- Mice
- Middle Aged
- Neuroblastoma/diagnosis
- Neuroblastoma/pathology
- Neuroectodermal Tumors, Primitive, Peripheral/diagnosis
- Neuroectodermal Tumors, Primitive, Peripheral/pathology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Sarcoma, Ewing/diagnosis
- Sarcoma, Ewing/pathology
- Staining and Labeling/methods
- Staining and Labeling/statistics & numerical data
- Wilms Tumor/diagnosis
- Wilms Tumor/pathology
Collapse
Affiliation(s)
- B E Halliday
- Department of Pathology and Laboratory Medicine, East Carolina University School of Medicine, Greenville, North Carolina, USA
| | | | | | | |
Collapse
|
27
|
Pellín A, Boix-Ferrero J, Carpio D, López-Terrada D, Carda C, Navarro S, Peydró-Olaya A, Triche TJ, Llombart-Bosch A. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. DIAGNOSTIC MOLECULAR PATHOLOGY : THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY, PART B 1997; 6:333-41. [PMID: 9559293 DOI: 10.1097/00019606-199712000-00005] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We report the status of the RB1, TP53, and MDM2 genes in human osteosarcomas and cell lines established from surgical specimens and transplanted into athymic naked mice. By using reverse transcriptase-polymerase chain reaction (RT-PCR) as a prescreening technique and posterior sequencing, we observe new mutations in the RB1 gene, notably a duplication in tandem of exons 3 through 6. TP53 mutations appear in codons most frequently mutated in osteosarcomas. We have not seen MDM2 gene amplification in any reported case. These molecular alterations appear in different osteosarcomas not simultaneously present in the same tumor sample. A link has been described between these three genes in the pathways that control the cell cycle and the tumoral progression, but their functions are probably independent in the development of osteosarcomas. TP53 mutations appear in adult patients, whereas RB1 alterations occur mostly in younger patients.
Collapse
Affiliation(s)
- A Pellín
- Department of Pathology, Medical School, University of Valencia, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pawel BR, Hamoudi AB, Asmar L, Newton WA, Ruymann FB, Qualman SJ, Webber BL, Maurer HM. Undifferentiated sarcomas of children: pathology and clinical behavior--an Intergroup Rhabdomyosarcoma study. MEDICAL AND PEDIATRIC ONCOLOGY 1997; 29:170-80. [PMID: 9212841 DOI: 10.1002/(sici)1096-911x(199709)29:3<170::aid-mpo3>3.0.co;2-a] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Undifferentiated soft tissue sarcoma (UND-STS) is the most poorly defined tumor eligible for intergroup Rhabdomyosarcoma Studies (IRS). Recent IRS UND-STS experience was reviewed to assess the histologic characteristics and clinical behavior of undifferentiated sarcomas. Of the 1,527 patients entered on IRS-III and IRS pilot-IV, 96 had tumors classified by the IRS Pathology Committee as UND-STS. Of these, 52 had adequate histologic material for this study. After application of immunohistochemistry, 18 tumors were reclassified, mostly as embryonal rhabdomyosarcomas (RMS), primitive neuroectodermal tumors, and intraabdominal desmoplastic small found cell tumors. The remaining 34 UND-STS had a diffuse hypercellular histologic pattern made up of sheets of medium-sized cells. The tumor cells had a minimal to moderate amount of cytoplasm and a variable nuclear morphology, predominately vesicular with finely granular chromatin. Except for reactivity with antibodies against vimentin, most tumors had a negative immunohistochemical profile. The 5 year Kaplan-Meier survival estimate for patients with non-metastatic disease was 72%, a significant improvement when contrasted with patients diagnosed to have UND-STS in IRS-I and IRS-II.
Collapse
Affiliation(s)
- B R Pawel
- Department of Pathology, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Nogueira E, Navarro S, Pellín A, Llombart-Bosch A. Activation of TRK genes in Ewing's sarcoma. Trk A receptor expression linked to neural differentiation. DIAGNOSTIC MOLECULAR PATHOLOGY : THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY, PART B 1997; 6:10-6. [PMID: 9028732 DOI: 10.1097/00019606-199702000-00003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Trk receptors have been identified by immunohistochemical methods in primitive neuroectodermal tumor (PNET)/Ewing's sarcoma (ES). However, the presence of different members of the Trk family of receptors in PNET/ES has not been specified. We have examined whether Trk A, B, and C receptors are specifically expressed in ES both with and without features of neural differentiation. Ten ES tumors (five primary tumors of bone and five extraosseous tumors transplanted into nude mice) were investigated for expression of Trk receptors by immunohistochemistry and reverse transcription-polymerase chain reaction. One primary ES and the five grafted ES tumors exhibited signs of neural differentiation; the remaining four primaries were undifferentiated ES. Other tumor types were analyzed as controls; they included three neuroblastomas (NB), two lymphomas, and single cases of pheochromocytoma (PHEO), schwannoma (SCHW), osteosarcoma, and carcinoma of breast, colon, and kidney. Trk receptors were detected in paraffin-embedded tumor tissue sections by means of a pan-Trk polyclonal antibody raised against the 14 carboxy-terminal residues of gp140trk, and trk A, B, and C transcripts were specifically detected by polymerase chain reaction-based amplification on cDNAs derived from tumor RNA with MuLV reverse transcriptase. Reactivity to the pan-Trk antibody was exhibited by six ES tumors, the three NBs, and the single PHEO and SCHW cases; immunoreactivity was restricted to differentiated tumors, in the case of ES. Tumor types positive for immunostaining were also distinguished by containing transcripts of TRK genes. However, the trk A, B, and C expression pattern of ES differed from that of NBs, PHEO, and SCHW. Transcripts of trk A, B, and C were detected in seven, four, and one case of ES, respectively, and in five, two, and five cases of NB, PHEO, and SCHW, respectively. Interestingly, all differentiated ES tumors contained trk A transcripts. Tumors of neuroectodermal phenotype and/or derivation were thus characterized by a distinct consensus expression pattern: trk A+/B-/C+ for differentiated ES and trk A+/B-/C+ for NB-PHEO-SCHW. These results indicate that the TRK gene family is frequently activated in ES; they also suggest that Trk A receptor is a feature of ES with neural differentiation, whereas Trk B and C receptors seem to be present in undifferentiated ES.
Collapse
MESH Headings
- Animals
- Cell Differentiation/genetics
- Gene Expression Regulation, Neoplastic
- Membrane Proteins/biosynthesis
- Membrane Proteins/genetics
- Mice
- Neuroectodermal Tumors, Primitive/genetics
- Neuroectodermal Tumors, Primitive/metabolism
- Neurons/cytology
- Protein-Tyrosine Kinases/biosynthesis
- Protein-Tyrosine Kinases/genetics
- Proto-Oncogene Proteins/biosynthesis
- Proto-Oncogene Proteins/genetics
- Receptor Protein-Tyrosine Kinases/biosynthesis
- Receptor Protein-Tyrosine Kinases/genetics
- Receptor, Ciliary Neurotrophic Factor
- Receptor, trkA
- Receptor, trkC
- Receptors, Nerve Growth Factor/biosynthesis
- Receptors, Nerve Growth Factor/genetics
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/metabolism
Collapse
Affiliation(s)
- E Nogueira
- Department of Pathology, University of Valencia Medical School, Spain
| | | | | | | |
Collapse
|
30
|
Newton WA. Classification of rhabdomyosarcoma. CURRENT TOPICS IN PATHOLOGY. ERGEBNISSE DER PATHOLOGIE 1995; 89:241-59. [PMID: 7882712 DOI: 10.1007/978-3-642-77289-4_12] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- W A Newton
- Intergroup Rhabdomyosarcoma Study Pathology Center, Children's Hospital, Columbus, OH 43205
| |
Collapse
|
31
|
Furue M, Okamoto T, Ikeda M, Tanaka Y, Sasaki Y, Nishihira K, Sato JD. Primitive neuroectodermal tumor cell lines derived from a metastatic pediatric tumor. In Vitro Cell Dev Biol Anim 1994; 30A:813-6. [PMID: 7894770 DOI: 10.1007/bf02639388] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
32
|
Abstract
BACKGROUND In vitro, tissue culture-associated differentiation assays have facilitated the identification of multiple tumor-cell types. METHODS We have investigated the capability of differentiation of three extraosseous Ewing's sarcoma cell lines toward a neural and muscular direction by in vitro stimulation with dibutyryl cyclic adenosine-monophosphate (db cAMP) and 5-azacytidine, respectively. RESULTS Elongation of cytoplasmic processes and increase of neural markers chromogranin, S-100 protein, and glial fibrillary acidic protein were observed after db cAMP treatment of these lines and neurosecretory granules as well as myelin figures were demonstrated ultrastructurally. These results support the existence of several pathways of neural differentiation in vitro--neuroblastic, Schwannian, and central glial--in stages of maturation more advanced than those previously reported in Ewing's sarcoma of bone. The cell lines showed no definitive myoblastic differentiation after 5-azacytidine treatment. CONCLUSIONS These data suggest that these three extraosseous Ewing's sarcoma cell lines configurate a heterogeneous group of tumors with respect to capability of differentiation into the neural lineage, arrested at more advanced stages of neural crest development than Ewing's sarcoma of bone and without capability of myoblastic differentiation with 5-azacytidine.
Collapse
Affiliation(s)
- R Noguera
- Department of Pathology, Medical School, University of Valencia, Spain
| | | | | | | |
Collapse
|
33
|
Pellin A, Boix J, Blesa JR, Noguera R, Carda C, Llombart-Bosch A. EWS/FLI-1 rearrangement in small round cell sarcomas of bone and soft tissue detected by reverse transcriptase polymerase chain reaction amplification. Eur J Cancer 1994; 30A:827-31. [PMID: 7522496 DOI: 10.1016/0959-8049(94)90300-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Recent cloning of the t(11;22) region has led to the detection of a number of sequences involved in the breakpoints by substituting a sequence which encodes a putative RNA binding domain for that of the DNA binding domain of the human homologue of murine FLI-1. Several tumours display consistent translocation at t(11;22) (q24;q12), a finding that suggests these fusion transcripts could be expressed and detected by reverse transcriptase polymerase chain reaction amplification. To date, only a small number of Ewing's sarcomas (Es) and peripheral neuroectodermal tumours (pPNET) of bone have been tested with this novel molecular biology approach. In this study, we confirmed the presence of the three putative chimaeric transcripts on 7 cases of Es and pPNET sarcomas of bone and soft tissue, providing 100% positivity for the tested tumours. For comparative purposes, a number of other neuroectodermal tumours were analysed with negative results: esthesioneuroblastoma, retinoblastoma, Schwannoma. A primitive soft tissue sarcoma (ectomesenchymoma) with a 22 chromosome rearrangement did not express any transcript, nor did a number of non-neuroectodermal small round cell sarcomas of soft tissue (rhabdomyosarcomas) and bone (microcellular osteosarcoma), conventional bone sarcomas, leiomyosarcomas, malignant fibrous histiocytomas and synovial sarcomas. These results reinforce the value of molecular biology techniques for the correct assessment of histology difficult evaluable neoplasms, such as the group of small round cell tumours within the Es family.
Collapse
Affiliation(s)
- A Pellin
- Department of Pathology, Medical School, University of Valencia, Spain
| | | | | | | | | | | |
Collapse
|
34
|
Ramani P, Rampling D, Link M. Immunocytochemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity. Histopathology 1993; 23:557-61. [PMID: 8314240 DOI: 10.1111/j.1365-2559.1993.tb01243.x] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
12E7 is a monoclonal antibody to the MIC2 gene product and can be applied to formalin-fixed, paraffin-embedded tissue. The diagnostic utility of 12E7 as a marker of Ewing's sarcoma and peripheral neuroectodermal tumour was assessed. Immunocytochemical studies were performed on 120 small round-cell tumours from children and adolescents. Immunoreactivity for 12E7 was seen in 13 of 15 Ewing's sarcomas. 14 of 15 peripheral neuroectodermal tumours, four of 14 embryonal rhabdomyosarcoma, seven of 11 T-lymphoblastic lymphomas and one T-cell acute lymphoblastic leukaemia. Immunoreactivity was located on the cell-membrane of Ewing's sarcomas, peripheral neuroectodermal tumours and lymphoid tumours while rhabdomyosarcomas showed weak, cytoplasmic staining in differentiated rhabdomyoblasts. Studies on alveolar rhabdomyosarcomas (n = 10), acute myeloid leukaemias (3), B-lymphoblastic lymphomas (8), blastema-rich nephroblastomas (9), neuroblastomas (20) and retinoblastomas (10) as well as single examples of B-cell acute lymphoblastic leukaemia, Ki-1 anaplastic lymphoma of indeterminate phenotype and intra-abdominal desmoplastic tumour with divergent differentiation were negative. 12E7 is a sensitive marker for the Ewing's sarcoma/peripheral neuroectodermal group of tumours and is useful in distinguishing them from neuroblastoma and blastema-rich nephroblastoma. However, immunopositivity for 12E7 should be interpreted in conjunction with the results of neural and lymphoid markers.
Collapse
Affiliation(s)
- P Ramani
- Department of Histopathology, Hospital for Sick Children, London, UK
| | | | | |
Collapse
|
35
|
|
36
|
Shishikura A, Ushigome S, Shimoda T. Primitive neuroectodermal tumors of bone and soft tissue: histological subclassification and clinicopathologic correlations. ACTA PATHOLOGICA JAPONICA 1993; 43:176-86. [PMID: 8388151 DOI: 10.1111/j.1440-1827.1993.tb01129.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Recent reports of Ewing's sarcoma (EW) and extraskeletal Ewing's sarcoma (EEW) support the hypothesis that these tumors are neuroectodermal in origin. Primitive neuroectodermal tumors (PNET) of bone (32 cases) and soft tissue (25 cases) including those previously categorized as EW in 27 cases and EEW in 15 cases were carefully studied histologically, immunocytochemically and morphometrically, focusing on tumor cell differentiation. This study attempts to subclassify these tumors on the basis of the size of tumor cells and nuclei, their variations (uniformity or diversity), arrangement of tumor cells (rosette or non-rosette), focal differentiation to larger ganglion-like cells, and staining intensity for neural markers. All tumors were histologically subclassified as small, medium or large cell types, three basic subtypes (rosette type, abortive rosette type, non-rosette type) and four complementary subtypes (fibrillary type, non-fibrillary type, angiomatoid type, ganglion cell type). Classic EW or EEW is consistent with small or medium, non-rosette, non-fibrillary type tumors, previously described large cell EW with large, non-rosette, fibrillary or non-fibrillary type tumors, and classic neuroectodermal tumor with small or medium, rosette, fibrillary type tumors, according to the present subclassification. Clinicopathologic correlations with the different subtypes are discussed. Long-term survival, more than 5 years, was seen in patients with small cell type, and those younger than 14 years of age.
Collapse
Affiliation(s)
- A Shishikura
- Department of Pathology, Jikei University School of Medicine, Tokyo, Japan
| | | | | |
Collapse
|
37
|
Ushigome S, Nakamori K, Nikaido T, Takagi M. Histologic subclassification of osteosarcoma: differential diagnostic problems and immunohistochemical aspects. Cancer Treat Res 1993; 62:125-37. [PMID: 8096726 DOI: 10.1007/978-1-4615-3518-8_16] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
38
|
Stephenson CF, Bridge JA, Sandberg AA. Cytogenetic and pathologic aspects of Ewing's sarcoma and neuroectodermal tumors. Hum Pathol 1992; 23:1270-7. [PMID: 1330877 DOI: 10.1016/0046-8177(92)90295-e] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Diagnostic classification of poorly differentiated, round cell, primitive neuroectodermal neoplasms, including Ewing's sarcoma, peripheral neuroepithelioma, Askin's tumor, and esthesioneuroblastoma, is challenging to the surgical pathologist using conventional histopathologic approaches because of very similar and overlapping morphologic and cytologic features. Furthermore, distinguishing these neoplasms from neuroblastoma, embryonal rhabdomyosarcoma, small cell osteogenic sarcoma, and non-Hodgkin's lymphoma can be difficult. This paper describes and reviews the cytogenetic and molecular genetic changes in these tumors and demonstrates how the ability to detect these changes has enabled a greater understanding of the histogenesis, classification, diagnosis, and prognosis of these neoplasms.
Collapse
MESH Headings
- Cell Transformation, Neoplastic
- Chromosome Aberrations
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 22
- Cytogenetics
- Diagnosis, Differential
- Humans
- Neoplasms, Nerve Tissue/genetics
- Neoplasms, Nerve Tissue/pathology
- Proto-Oncogenes
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/pathology
Collapse
Affiliation(s)
- C F Stephenson
- Cancer Center of Southwest Biomedical Research Institute, Scottsdale, AZ 85251
| | | | | |
Collapse
|
39
|
Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol 1992; 16:694-707. [PMID: 1530109 DOI: 10.1097/00000478-199207000-00008] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We studied the clinical and pathologic features of 78 malignant peripheral nerve sheath tumors in children less than or equal to 15 years of age. There were 42 boys and 36 girls, with a median age of 10 years. The majority of the tumors (42, or 54%) were central or axial in location; the rest were peripheral. Sixteen patients (21%) had a history of von Recklinghausen's disease. Fourteen (18%) had a malignant peripheral nerve sheath tumor arising in a nerve trunk or a neurofibroma and were unassociated with von Recklinghausen's disease. Patients typically presented with a painful mass of variable duration. Tumors ranged from 2 to 33 cm (median, 7.5 cm) and demonstrated a wide histologic spectrum that included spindled, epithelioid, and primitive neuroepithelial-like cells as well as heterologous elements (11). Immunohistochemical staining revealed S-100 protein in 28 of 50 cases (56%) as well as vimentin (13 of 21 cases, or 62%), Leu 7 (22 of 49 cases, or 45%), actin (eight of 20 cases, or 40%), and keratin (seven of 27 cases, or 26%). Survival status was known for 57 patients (73%). Kaplan-Meier estimates revealed a median survival of 45 months. Half of the patients had local recurrences at 12 months, and half had metastases at 24 months, most commonly to lungs, followed by lymph nodes, liver, bone, soft tissue, and brain. Age greater than or equal to 7 years, male sex, presence of von Recklinghausen's disease, central location, larger tumor size, and tumors with greater than or equal to 25% necrosis were found to be potentially significant adverse prognostic indicators by univariate analysis. Multivariate analysis revealed that larger tumor size, age greater than or equal to 7 years, tumor necrosis greater than or equal to 25%, and von Recklinghausen's disease to be independent adverse prognostic factors.
Collapse
Affiliation(s)
- J M Meis
- Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, D.C. 20306
| | | | | | | |
Collapse
|
40
|
Contesso G, Llombart-Bosch A, Terrier P, Peydro-Olaya A, Henry-Amar M, Oberlin O, Habrand JL, Dubousset J, Tursz T, Spielmann M. Does malignant small round cell tumor of the thoracopulmonary region (Askin tumor) constitute a clinicopathologic entity? An analysis of 30 cases with immunohistochemical and electron-microscopic support treated at the Institute Gustave Roussy. Cancer 1992; 69:1012-20. [PMID: 1310431 DOI: 10.1002/1097-0142(19920215)69:4<1012::aid-cncr2820690431>3.0.co;2-v] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The morphology and clinical outcome of 30 patients with malignant small round cell tumors located in the thoracopulmonary region (Askin tumor) are reported. Histologically, all tumors had similar patterns, with small round-to-oval cells and a lobulated stroma. Immunohistochemical analysis always resulted in positive staining for one or several neural markers. No significant differences were found compared with the immunomarkers in 26 typical Ewing's sarcomas located outside the thoracic wall. In three specimens, electron microscopy confirmed the presence of membrane-bound neurosecretory granules. It was confirmed that there is a remarkable similarity among all malignant small round cell tumors, including Askin tumor and Ewing's sarcoma. Overall survival was poor with a 2-year rate of 38% and a 6-year rate of 14%.
Collapse
Affiliation(s)
- G Contesso
- Department of Pathology, Institute Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|